The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Official Title: A Clinical Trial of MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer
Study ID: NCT03799913
Brief Summary: The goal of this clinical trial is to study the feasibility and efficacy of anti-MESO antigen receptors (CARs) T cell therapy for relapsed and refractory ovarian cancer.
Detailed Description: Primary Objectives 1.To determine the feasibility ad safety of anti-MESO CAR-T cells in treating patients with MESO-positive ovarian cancer. Secondary Objectives 1. To access the efficacy of anti-MESO CAR-T cells in patients with ovarian cancer. 2. To determine in vivo dynamics and persistency of anti- MESO CAR-T cells.
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: FEMALE
Healthy Volunteers: No
The Second Affiliated hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
Name: Jianwei Zhou, M.D.
Affiliation: Zhejiang University
Role: STUDY_CHAIR